Standard BioTools Inc. (LAB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LAB Revenue Growth
Revenue Breakdown (FY 2025)
LAB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
LAB Revenue Analysis (2014–2025)
As of May 8, 2026, Standard BioTools Inc. (LAB) generated trailing twelve-month (TTM) revenue of $65.7 million, reflecting significant decline in growth of -48.2% year-over-year. The most recent quarter (Q1 2026) recorded $21.1 million in revenue, up 556.3% sequentially.
Looking at the longer-term picture, LAB's 5-year compound annual growth rate (CAGR) stands at -9.2%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $174.4 million in 2024.
Revenue diversification analysis shows LAB's business is primarily driven by Product (42%), Consumables (25%), and Instruments (17%).
When compared to Healthcare sector peers including AZTA (+1.8% YoY), NTRA (+35.9% YoY), and PACB (+3.9% YoY), LAB has underperformed the peer group in terms of revenue growth. Compare LAB vs AZTA →
LAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LABCurrent | $66M | -48.2% | -9.2% | -109.3% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 SEER | $14M | +14.5% | +160.6% | -717.7% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% |
LAB Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $85.3M | -51.1% | $42.5M | 49.9% | $-93,305,000 | -109.3% |
| 2024 | $174.4M | +64.0% | $84.3M | 48.3% | $-175,236,000 | -100.5% |
| 2023 | $106.3M | +8.6% | $50.5M | 47.4% | $-76,600,000 | -72.0% |
| 2022 | $97.9M | -25.0% | $37.1M | 37.8% | $-116,205,000 | -118.6% |
| 2021 | $130.6M | -5.5% | $69.4M | 53.1% | $-67,459,000 | -51.7% |
| 2020 | $138.1M | +17.8% | $83.3M | 60.3% | $-51,036,000 | -36.9% |
| 2019 | $117.2M | +3.8% | $64.3M | 54.8% | $-51,839,000 | -44.2% |
| 2018 | $113.0M | +10.8% | $61.6M | 54.6% | $-48,164,000 | -42.6% |
| 2017 | $101.9M | -2.4% | $52.0M | 51.0% | $-58,360,000 | -57.3% |
| 2016 | $104.4M | -8.9% | $58.4M | 55.9% | $-73,190,000 | -70.1% |
See LAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLAB — Frequently Asked Questions
Quick answers to the most common questions about buying LAB stock.
Is LAB's revenue growth accelerating or slowing?
LAB revenue declined -48.2% year-over-year, contrasting with the 5-year CAGR of -9.2%. TTM revenue fell to $66M. This reverses the prior growth trend.
What is LAB's long-term revenue growth rate?
Standard BioTools Inc.'s 5-year revenue CAGR of -9.2% reflects the variable expansion pattern. Current YoY growth of -48.2% is below this long-term average.
How is LAB's revenue distributed by segment?
LAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.